The emergence of the Cicada COVID variant has sparked urgent health concerns as it spreads globally, including in India. This variant, classified as BA.3.2 and part of the Omicron family, was first identified in South Africa in November 2024.
With over 70 mutations compared to the original Wuhan strain, the Cicada variant carries approximately 75 mutations in total, with more than 50 of these located in the spike protein. This raises questions about its potential to evade immunity from previous infections or vaccinations.
Symptoms associated with the Cicada variant include cough, extreme fatigue, runny nose, headache, sore throat, mild fever, muscle and joint pain, loss of taste or smell, night sweats, and rash. However, it has not been confirmed to cause more severe illness than previous variants.
As of now, the variant has been detected in 22 countries, with the first confirmed case in the United States reported in June 2025. By January 2026, three patients in the U.S. had been confirmed to have contracted the variant, all of whom recovered.
Health officials are closely monitoring the situation. Dr. Robert Hopkins Jr. noted, “It is possible we will see Cicada become the dominant strain in the U.S., but that is by no means certain.” The CDC emphasized the importance of tracking the spread of BA.3.2 to gather valuable information regarding its potential impact on immunity.
In India, the detection of the Cicada variant raises alarms as health authorities prepare to respond to any potential outbreaks. The situation is being closely monitored, and public health measures may be adjusted accordingly.
As the world grapples with the ongoing pandemic, the emergence of new variants like Cicada underscores the need for continued vigilance. Details remain unconfirmed regarding the variant’s severity and its implications for public health.
